ArticleMalaria journal2026
Pharmaceutical quality of artemether-lumefantrine in Rwanda's public health supply chain: a cross-sectional post-market surveillance study.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSubstandard and falsified (S&F) antimalarial medicines undermine malaria control efforts across sub-Saharan Africa, with an estimated 19% of antimalarials failing to meet quality standards and contributing to 40,000-160,000 preventable deaths annually. ACTs, particularly artemether-lumefantrine (AL), are the cornerstone of malaria treatment, yet their effectiveness is threatened by poor pharmaceutical quality and emerging drug resistance. This study evaluated the pharmaceutical quality of AL circulating in Rwanda's public health supply chain to assess compliance with international pharmacopeial standards.
methodsA cross-sectional survey was conducted in February 2023 across eight districts representing all five provinces of Rwanda and encompassing both high- and low-malaria transmission settings. A total of 19 samples (3588 AL tablets) were sampled from three supply chain levels: Rwanda Medical Supply (RMS) headquarters and district branches, health centers, and Community Health Workers. Samples underwent comprehensive quality testing at a WHO-recognized laboratory, including visual inspection, tablet weight determination, high-performance liquid chromatography (HPLC) assay for artemether and lumefantrine content (acceptance range: 95.0-105.0%), and dissolution testing using pharmacopeial methods. The study followed Medicine Quality Assessment Reporting Guidelines (MEDQUARG) guidelines for medicine quality surveillance.
resultsAll 19 samples (3588 tablets, 100%) met international pharmacopeial quality standards across all testing parameters. Visual inspection revealed no packaging defects, labeling errors, or tablet abnormalities. Tablet weight uniformity complied with specifications for both dispersible tablets (mean: 356.27 mg; range: 355.04-357.65 mg; specification: 339.50-360.50 mg) and regular tablets (mean: 241.63 mg; range: 239.79-242.72 mg). Artemether assay values ranged from 97.3 to 99.4% (mean: 98.7%), while lumefantrine ranged from 97.3 to 104.3% (mean: 99.2%), with all samples meeting the 95.0-105.0% acceptance criteria. Dissolution testing demonstrated 100% compliance for both active pharmaceutical ingredients across all samples.
conclusionsAll AL samples met international quality standards, contrasting with sub-Saharan Africa's 19% failure rate. Rwanda's centralized procurement, regulatory oversight, and WHO-prequalified sourcing demonstrate a replicable model for ensuring antimalarial quality and combating drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.